{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    8,
    18,
    24,
    43,
    59
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Exceptional Circumstances Guidance",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.10",
        "sectionTitle": "Appendix 10: Provisions for Changes in Study Conduct During Exceptional Circumstances",
        "description": "Reference from Schedule of Activities for additional guidance during pandemics or natural disasters"
      },
      {
        "id": "ref_2",
        "name": "Diabetes Confirmation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.2.3",
        "sectionTitle": "Definition and Management of Incident Diabetes",
        "description": "Reference from OGTT section for diabetes diagnosis confirmation procedures"
      },
      {
        "id": "ref_3",
        "name": "GI Symptoms Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6.2",
        "sectionTitle": "Management of Participants with Gastrointestinal Symptoms",
        "description": "Reference for managing participants with GI symptoms"
      },
      {
        "id": "ref_4",
        "name": "Excessive Weight Loss Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6.3",
        "sectionTitle": "Management of Participants with Perceived Excessive Weight Loss During the Additional 2-year Treatment Period for Participants with Prediabetes at Randomization",
        "description": "Reference for managing participants with perceived excessive weight loss"
      },
      {
        "id": "ref_5",
        "name": "GI Symptoms Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.9",
        "sectionTitle": "Appendix 9: Management of Gastrointestinal Symptoms",
        "description": "Reference for symptomatic medication management"
      },
      {
        "id": "ref_6",
        "name": "Drug Interruption Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1.1",
        "sectionTitle": "Study Drug Interruption Management",
        "description": "Reference for management of study drug after interruptions greater than 1 dose"
      },
      {
        "id": "ref_7",
        "name": "OGTT Standardized Protocol Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.7",
        "sectionTitle": "Appendix 7: Protocol GPHK Standardized Protocols for the Measurement of Height, Weight, Waist Circumference, Vital Signs, Electrocardiogram, and Oral Glucose Tolerance Test",
        "description": "Reference for OGTT procedures per Schedule of Activities"
      },
      {
        "id": "ref_8",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference for visit schedule and timing requirements"
      },
      {
        "id": "ref_9",
        "name": "Objectives and Endpoints Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3",
        "sectionTitle": "Objectives and Endpoints",
        "description": "Reference for key study objectives and endpoints modifications"
      },
      {
        "id": "ref_10",
        "name": "Participant Withdrawal Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2",
        "sectionTitle": "Participant Discontinuation/Withdrawal from the Study",
        "description": "Reference for pregnancy-related withdrawal procedures"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Please see table below for corresponding additional information",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 25
      },
      {
        "id": "annot_2",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 2
      },
      {
        "id": "annot_3",
        "text": "Placement of a venous cannula may not be required when a 2-hour OGTT is repeated to confirm the diagnosis of diabetes during the study, and only samples at 0 and 120 minutes for glucose measurement will be collected",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Appendix 7: Protocol GPHK Standardized Protocols",
        "pageNumber": 5
      },
      {
        "id": "annot_4",
        "text": "In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 2
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "b",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-10-04",
        "description": "Protocol Amendment (b) updating key study objectives and endpoints, clarifying incident diabetes definition, adding guidance for dose modification during additional 2-year treatment period, and updating statistical analyses",
        "amendmentNumber": "Amendment (b)"
      },
      {
        "id": "ver_2",
        "versionNumber": "a",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-07-24",
        "description": "First protocol amendment",
        "amendmentNumber": "Amendment (a)"
      },
      {
        "id": "ver_3",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-09-09",
        "description": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 10,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}